A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

Status
Active
Cancer Type
Ovarian Cancer
Trial Phase
Phase III
Eligibility
18 and over, Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01493505
Protocol IDs
20101129 (primary)
TRINOVA-3 20101129/ENGOT-ov2
Study Sponsor
Amgen, Incorporated

Summary

The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.